Estimating the cost of illness of acute Japanese encephalitis and sequelae care in Vietnam and Laos: A cross-sectional study.


Journal

PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676

Informations de publication

Date de publication:
2023
Historique:
received: 15 01 2023
accepted: 05 05 2023
medline: 13 6 2023
pubmed: 13 6 2023
entrez: 13 6 2023
Statut: epublish

Résumé

Japanese encephalitis (JE) is a leading cause of acute encephalitis syndrome and resulting neurological disability in Asia and the Western Pacific. This study aims to estimate the cost of acute care, initial rehabilitation and sequelae care, in Vietnam and Laos. We conducted a cross-sectional retrospective study using a micro-costing approach from the health system and household perspectives. Out-of-pocket direct medical and non-medical costs, indirect costs, and family impact were reported by patients and/or caregivers. Hospitalization costs were extracted from hospital charts. Acute costs covered expenditures from pre-hospital to follow-up visits while sequelae care costs were estimated from expenditures in the last 90 days. All costs are in 2021 US dollars. 242 patients in two major sentinel sites in the North and South of Vietnam and 65 patients in a central hospital in Vientiane, Laos, with laboratory-confirmed JE were recruited regardless of age, sex, and ethnicity. In Vietnam, the mean total cost was $3,371 per acute JE episode (median $2,071, standard error [SE] $464) while annual costs were $404 for initial sequelae care (median $0, SE $220) and $320 for long-term sequelae care (median $0, SE $108). In Laos, the mean hospitalization costs in acute stage were $2,005 (median $1,698, SE $279) and the mean annual costs were $2,317 (median $0, SE $2,233) for initial sequelae care and $89 (median $0, SE $57) for long-term sequelae care. In both countries, most patients did not seek care for their sequelae. Families perceived extreme impact from JE and 20% to 30% of households still had sustained debts years after acute JE. JE patients and families in Vietnam and Laos suffer extreme medical, economic, and social hardship. This has policy implications for improving JE prevention in these two JE-endemic countries.

Sections du résumé

BACKGROUND BACKGROUND
Japanese encephalitis (JE) is a leading cause of acute encephalitis syndrome and resulting neurological disability in Asia and the Western Pacific. This study aims to estimate the cost of acute care, initial rehabilitation and sequelae care, in Vietnam and Laos.
METHODOLOGY METHODS
We conducted a cross-sectional retrospective study using a micro-costing approach from the health system and household perspectives. Out-of-pocket direct medical and non-medical costs, indirect costs, and family impact were reported by patients and/or caregivers. Hospitalization costs were extracted from hospital charts. Acute costs covered expenditures from pre-hospital to follow-up visits while sequelae care costs were estimated from expenditures in the last 90 days. All costs are in 2021 US dollars.
PRINCIPAL FINDINGS RESULTS
242 patients in two major sentinel sites in the North and South of Vietnam and 65 patients in a central hospital in Vientiane, Laos, with laboratory-confirmed JE were recruited regardless of age, sex, and ethnicity. In Vietnam, the mean total cost was $3,371 per acute JE episode (median $2,071, standard error [SE] $464) while annual costs were $404 for initial sequelae care (median $0, SE $220) and $320 for long-term sequelae care (median $0, SE $108). In Laos, the mean hospitalization costs in acute stage were $2,005 (median $1,698, SE $279) and the mean annual costs were $2,317 (median $0, SE $2,233) for initial sequelae care and $89 (median $0, SE $57) for long-term sequelae care. In both countries, most patients did not seek care for their sequelae. Families perceived extreme impact from JE and 20% to 30% of households still had sustained debts years after acute JE.
CONCLUSIONS CONCLUSIONS
JE patients and families in Vietnam and Laos suffer extreme medical, economic, and social hardship. This has policy implications for improving JE prevention in these two JE-endemic countries.

Identifiants

pubmed: 37310946
doi: 10.1371/journal.pgph.0001873
pii: PGPH-D-23-00078
pmc: PMC10263309
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e0001873

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright: © 2023 Nguyen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Vaccine. 2012 Aug 10;30(37):5569-77
pubmed: 22698453
Bull World Health Organ. 2003;81(5):334-42
pubmed: 12856051
MMWR Morb Mortal Wkly Rep. 2017 Jun 09;66(22):579-583
pubmed: 28594790
Vaccine. 2010 Jun 23;28(29):4593-9
pubmed: 20470803
Southeast Asian J Trop Med Public Health. 1997 Mar;28(1):143-8
pubmed: 9322297
Vaccine X. 2022 Feb 05;10:100143
pubmed: 35243320
Bull World Health Organ. 2010 Aug 1;88(8):584-92
pubmed: 20680123
Bull World Health Organ. 2011 Oct 1;89(10):766-74, 774A-774E
pubmed: 22084515
PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2383
pubmed: 24069467
PLoS Negl Trop Dis. 2015 Mar 20;9(3):e0003630
pubmed: 25794009
Health Res Policy Syst. 2019 Dec 16;17(1):99
pubmed: 31842882
Int J Infect Dis. 2009 Nov;13(6):e389-93
pubmed: 19346144
J Trop Pediatr. 2011 Aug;57(4):241-4
pubmed: 20068031
J Family Med Prim Care. 2021 Nov;10(11):3991-3997
pubmed: 35136757
Vaccine. 2008 Aug 18;26(35):4456-60
pubmed: 18602436
NPJ Vaccines. 2021 Jun 15;6(1):82
pubmed: 34131150
J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):405-15
pubmed: 10727474
Lancet Glob Health. 2022 Feb;10(2):e186-e194
pubmed: 34951973
Am J Trop Med Hyg. 2020 Dec 21;104(2):567-575
pubmed: 33350379

Auteurs

Rose Slavkovsky (R)

PATH, Seattle, Washington, United States of America.

Hai Thanh Phan (HT)

School of Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, Vietnam.

Huong Thi Thu Nguyen (HTT)

National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.

Souphaphone Vannachone (S)

Lao-Oxford University-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People's Democratic Republic.

Dang Hai Le (DH)

National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.

Audrey Dubot-Pérès (A)

Lao-Oxford University-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People's Democratic Republic.
Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Manivanh Vongsouvath (M)

Lao-Oxford University-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People's Democratic Republic.

Son Thai Dinh (ST)

School of Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, Vietnam.

Anthony A Marfin (AA)

PATH, Seattle, Washington, United States of America.

G William Letson (GW)

PATH, Seattle, Washington, United States of America.

Huong Minh Vu (HM)

World Health Organization Viet Nam, Hanoi, Vietnam.

Dung Chi Tham (DC)

PATH, Hanoi, Vietnam.

Mayfong Mayxay (M)

Lao-Oxford University-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People's Democratic Republic.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Institute of Research and Education Development, University of Health Sciences, Vientiane, Lao People's Democratic Republic.

Elizabeth A Ashley (EA)

Lao-Oxford University-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People's Democratic Republic.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Thai Quang Pham (TQ)

National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.

Clint Pecenka (C)

PATH, Seattle, Washington, United States of America.

Classifications MeSH